CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in <i>PIK3CA</i> -Mutant Gastric Cancer
Lyla J. Stanland(Tenax Therapeutics (United States)), Micah A. Luftig(Duke University), Kris C. Wood(Duke University), Patrick Tan(SingHealth), Yunqiang Chu(Duke-NUS Medical School), Hazel X. Ang(Duke University), Jacob P. Hoj(Duke University)
Cited by 13
Related Papers
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Enabling Technologies for Personalized and Precision Medicine
|Trends in biotechnology|2020|483
Genomic basis for RNA alterations in cancer
|Nature|2020|424
Profiling MicroRNA Expression in Hepatocellular Carcinoma Reveals MicroRNA-224 Up-regulation and Apoptosis Inhibitor-5 as a MicroRNA-224-specific Target
|Journal of Biological Chemistry|2008|363
Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
|Cancer Research|2011|363